Recent studies have indicated that C-MYC and MYCL1 may be the potential targets for SCLC, which could modulate the tumor microenvironment and intratumoral heterogeneity in SCLC in vivo and vitro [18, 19]. The gene discussed is MYC; the disease is neoplasm.